Evidence map›Paper›PMID 34359424›Full record

ArticleFoods (Basel, Switzerland)2021

Engineering Concanavalin B to Release Bioactive Peptides against Metabolic Syndrome.

Diego Armando Maldonado-Torres, G Janet Jara-Romero, Flor de Fátima Rosas-Cárdenas, D Alejandro Fernández-Velasco, Silvia Luna-Suárez

Open access · goldAbstract read
In one paragraph

Article in Foods (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 94% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Diego Armando Maldonado-TorresCentro de Investigación en Biotecnología Aplicada, Instituto Politécnico Nacional, CIBA-IPN, Carretera Estatal Tecuexcomac-Tepetitla Km. 1.5, Tepetitla 90700, Mexico.
G Janet Jara-RomeroCentro de Investigación en Biotecnología Aplicada, Instituto Politécnico Nacional, CIBA-IPN, Carretera Estatal Tecuexcomac-Tepetitla Km. 1.5, Tepetitla 90700, Mexico.
Flor de Fátima Rosas-CárdenasCentro de Investigación en Biotecnología Aplicada, Instituto Politécnico Nacional, CIBA-IPN, Carretera Estatal Tecuexcomac-Tepetitla Km. 1.5, Tepetitla 90700, Mexico.
D Alejandro Fernández-VelascoLaboratorio de Fisicoquímica e Ingeniería de Proteínas, Departamento de Bioquímica, Facultad de Medicina, UNAM, Ciudad de México 04510, Mexico.
Silvia Luna-SuárezCentro de Investigación en Biotecnología Aplicada, Instituto Politécnico Nacional, CIBA-IPN, Carretera Estatal Tecuexcomac-Tepetitla Km. 1.5, Tepetitla 90700, Mexico.
Instituto Politécnico Nacional · MXUniversidad Nacional Autónoma de México · MX

Funding

Consejo Nacional de Ciencia y Tecnología 256478Secretaría de Investigación y Posgrado, Instituto Politécnico Nacional 20210150
6 · The paper itself

Abstract

Metabolic syndrome is a severe public health issue characterized by multiple metabolic disturbances. Current treatments prescribe a particular drug for each of them, producing multiple side effects. As a first step towards a more integral approach, we applied our recently described methodology to design single proteins, based in the Concanavalin B scaffold (1CNV), that contain several bioactive peptides (BPs), including antioxidant and lipid-lowering activities as well as inhibitors of dipeptidyl peptidase IV (DPPIV) and the angiotensin converting enzyme. Modified Concanavalin (CNV44), the designed protein that showed the best in silico properties, was expressed in high yields in

Indexed as

ACEIantioxidant activitybioactive peptidesDPPIVlipid-loweringmetabolic syndromeprotein engineering

Identifiers

PMID34359424
PMCPMC8307266
OpenAlexW3180799529

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.